Safia Sultana Munir, Saima Jabeen, Nusrat Alvi, Dilawar Khan, Bilal Bin Younis, Muhammad Khan.
Role of Orlistat Combined with Life Style in the Management of Obese patients with Polycystic Ovarian Syndrome.
Pak J Med Health Sci Jan ;12(2):477-80.

Background: Obesity is frequently present in women with polycystic ovarian syndrome (PCOS) and aggravates insulin resistance (IR) and hyperandrogenemia. Aim: To compare the effects of orlistat combined with life style changes in obese women as compared to lifestyle changes only, on ovulation rate and decrease in body mass index, waist circumference and hyperandrogenemia. Design: Randomized Control Trial. Setting: Department of Obs/Gynae Shalamar Hospital Lahore. Methods: Cohort of 45 women with diagnoses of PCOS and BMI ≥ 30 were divided in two groups. Group A (n=30) were instructed to receive cap orlistat 120 BD + low caloric diet exercise and Group B (n= 15) will be followed low caloric diet and exercise only for 12 weeks. Outcome measures: The primary outcome measure were occurrence of ovulation as detected by Day-21 serum progesterone (> 4ng/ml) and fall in BMI. Secondary outcome measures were include changes in hip and waist circumference and changes in androgen profile as measured as free androgen index . Results: Study Depicted significant reduction in BMI and waist circumference as well as ovulation rate of 69.02% with Orlistat over period of 3 months as compared to diet only group with ovulation rate of 9.09%. FAI was significant (P=.001) in orlistat group as compared to diet group . Conclusion: Orlistat is safe anti-obesity drug with minimal side effects and can achieve significant reduction in BMI and waist circumference with 70% ovulation rate over shorter period of time Larger studies are required to study effect of orlistat on lipid profile and insulin resistance.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com